Publications of Pavel Marichal-Gallardo
All genres
Journal Article (14)
1.
Journal Article
14 (1), 17039 (2024)
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals. Scientific Reports 2.
Journal Article
108, 97 (2024)
Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus. Applied Microbiology and Biotechnology 3.
Journal Article
13, 20936 (2023)
Generation of “OP7 chimera” defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice. Scientific Reports 4.
Journal Article
26 (2), 105949 (2023)
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. iScience 5.
Journal Article
15 (9), 1872 (2023)
Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro. Viruses 6.
Journal Article
118 (10), pp. 3996 - 4013 (2021)
Towards integrated production of an influenza A vaccine candidate with MDCK suspension cells. Biotechnology and Bioengineering 7.
Journal Article
118 (12), pp. 4720 - 4734 (2021)
A high cell density perfusion process for Modified Vaccinia virus Ankara production: process integration with inline DNA digestion and cost analysis. Biotechnology and Bioengineering 8.
Journal Article
19 (1), 91 (2021)
Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles. BMC Biology 9.
Journal Article
105 (1), pp. 129 - 146 (2021)
OP7, a novel influenza A virus defective interfering particle: production, purification, and animal experiments demonstrating antiviral potential. Applied Microbiology and Biotechnology 10.
Journal Article
13 (8), pp. 1981 - 1989 (2021)
Multi-enzyme cascades for the in vitro synthesis of guanosine diphosphate L-fucose. ChemCatChem 11.
Journal Article
32 (17-18), pp. 959 - 974 (2021)
Single-use capture purification of adeno-associated viral gene transfer vectors by membrane-based steric exclusion chromatography. Human Gene Therapy 12.
Journal Article
10 (7), 1756 (2021)
Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. Cells 13.
Journal Article
37 (47), pp. 7019 - 7028 (2019)
Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1. Vaccine 14.
Journal Article
1483 (3), pp. 110 - 119 (2017)
Steric exclusion chromatography for purification of cell culture-derived influenza A virus using regenerated cellulose membranes and polyethylene glycol. Journal of Chromatography A Meeting Abstract (2)
15.
Meeting Abstract
A single-use chromatographic purification platform for viral gene transfer vectors & viral vaccines. In Proceedings Advancing Manufacture of Cell and Gene Therapies VI, 92. Advancing Manufacture of Cell and Gene Therapies VI, Loews Coronado Bay Hotel Coronado, California, USA, January 27, 2019 - January 31, 2019. (2019)
16.
Meeting Abstract
Purifying viruses with a sheet of paper: Single-use steric exclusion chromatography as a capture platform for vaccine candidates. In Vaccine Technology VII, 128. Vaccine Technology VII, Mont Tremblant, Canada, June 17, 2018 - June 22, 2018. (2018)
Talk (13)
17.
Talk
Engineered defective interfering particles of influenza A virus for antiviral treatment. 33rd Annual Meeting of the Society for Virology (GfV), Vienna (Austria) (2024)
18.
Talk
Genetic engineering of Influenza A virus defective interfering particles towards improved antiviral efficacy and potential use as a live vaccine. Vaccine Technology IX, Los Cabos (Mexico) (2024)
19.
Talk
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 17th Vaccine Congress, Glasgow (Scotland) (2023)
20.
Talk
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)